Home
Home
  • Home
  • About Us About Us
    • Overview
    • Who we are
    • Why we provide advice
    • What are health technologies
    • Meetings
    • News
    • Who we work with
    • Contact Us
  • What We Do What We Do
    • Overview
    • Our Strategy
    • Work programme
    • Range of advice products
    • Quarterly Bulletin of advice
    • Early HTA Advice Service
  • Our Advice
  • Request Advice Request Advice
    • Overview
    • Form for requesting advice
  • Get Involved Get Involved
    • Overview
    • Contribute to advice
    • NHS boards
    • Patient and Public Involvement
    • Industry Involvement
    • Observe a council meeting
    • DOI Form

Advice Statement

  • Home
  • Our Advice
  • Left atrial appendage occlusion (LAAO) in patients with atrial fibrillation who have contraindications to oral anticoagulation

Title

Output Type

Speciality

Published

Title

Left atrial appendage occlusion (LAAO) in patients with atrial fibrillation who have contraindications to oral anticoagulation

Output Type

Advice Statement

Speciality

Cardiovascular System

Published

1 August 2019

Recommendation for NHSScotland

Left atrial appendage occlusion (LAAO) may be offered to patients with non-valvular atrial fibrillation deemed to be at high risk of ischaemic stroke, who have absolute contraindications to oral anticoagulation with warfarin and direct oral anticoagulants. Prior to undergoing the LAAO procedure, an individual patient risk assessment must be carried out by a multidisciplinary team. The potential future benefits of LAAO, the risks associated with the procedure, and the need for long-term antiplatelet therapy, should be discussed with each patient prior to making a treatment decision.

LAAO procedure volume per centre should be maximised to support optimal patient outcomes and ensure clinical experience is achieved and retained.

NHSScotland is required to consider the Scottish Health Technologies Group (SHTG) advice.

What were we asked to look at?

We were asked us to provide advice on the use of LAAO in patients with atrial fibrillation and contraindications to oral anticoagulation.

Why is this important?

Patients with atrial fibrillation have a substantially increased risk of ischaemic stroke compared with the general population. The standard of care for ischaemic stroke prevention in patients with atrial fibrillation is long-term anticoagulant therapy with warfarin or a direct oral anticoagulant (apixaban, dabigatran, edoxaban, or rivaroxaban). However, some patients with atrial fibrillation have contraindications to oral anticoagulation, meaning they cannot receive this treatment and hence remain at increased risk of having an ischaemic stroke. LAAO involves inserting a device designed to block the left atrial appendage of the heart where many of the blood clots that lead to ischaemic stroke in atrial fibrillation patients are thought to form. LAAO may therefore be an option for patients with atrial fibrillation and contraindications to oral anticoagulation.

Referred by

The National Advisory Committee for Heart Disease

Download icon
Download Advice
pdf (1 MB)
Download icon
Download Plain Language Summary
pdf (542 KB)

Connect with Us

Please let us know if you'd like to receive regular updates on our work.


Last Updated: 21 July 2022

Scottish Health Technologies Group

© 2021, All rights reserved

  • Accessibility
  • Respecting your privacy
  • Cookies
  • Healthcare Improvement Scotland Website
  • Find us on Twitter
  • Freedom of Information

Tell us what you think


We'd love to hear your views

Was our advice useful?  Did you find what you were looking for on our website?